The Asia Pacific pharmaceutical CDMO market size was estimated at USD 74.04 billion in 2025 and is predicted to reach around USD 156.91 billion by 2035, expanding at a CAGR of 7.80% from 2026 to 2035. Growing focus on R&D and the rising trend of outsourcing drug development and manufacturing are driving the market..

Asia Pacific Pharmaceutical CDMO Market Statical Scope

The Asia -Pacific pharmaceutical CDMO market is experiencing strong growth, driven by rising outsourcing from global pharma and biotech companies seeking lower development costs, faster scaling, and flexible manufacturing networks across countries like India, China, South Korea, Japan, Singapore, and Taiwan.

The market is evolving beyond traditional small -molecule manufacturing toward more advanced segments such as biologics , biosimilars , sterile injectables, antibody -drug conjugates (ADCs), and cell and gene therapy . This shift is prompting CDMOs to invest in specialized facilities and advanced production platforms.

Asia Pacific Pharmaceutical CDMO Market Share, By Service Type, 2025 (%)

• Finished dosage formulation (FDF) development and manufacturing - Finished dosage formulation (FDF) development and manufacturing lead the market, holding a share of 44%, driven by increasing outsourcing of formulation processes and rising demand for complex and specialized dosage forms.
• Active pharmaceutical ingredient (API) manufacturing - Active pharmaceutical ingredient (API) manufacturing accounts for a share of 41%, supported by expanding generic drugs production, cost advantages in the region, and increasing outsourcing of bulk drug manufacturing by global pharmaceutical companies.
• Secondary packaging - Secondary packaging holds 15% share, driven by growing regulatory requirements for labeling and serialization, and demand for efficient packaging and supply chain solutions.

Asia Pacific Pharmaceutical CDMO Market Share, By Research Phase, 2025 (%)

• Phase III - Phase III leads the market, holding a share of 32%, driven by increasing late -stage clinical development activities and demand for large -scale manufacturing and commercialization support.
• Phase II - Phase II accounts for a significant share of 20%, supported by rising focus on efficacy studies and expansion of mid -stage clinical pipelines.
• Phase IV - Phase IV captures 16%, supported by growing emphasis on post -marketing surveillance, real -world evidence generation, and lifecycle management of approved drugs.
• Pre -clinical - pre -clinical phase holds 18%, driven by increasing research and development activities and strong drug discovery efforts across the region.

Top Companies in the Asia Pacific Pharmaceutical CDMO Market

• Bushu Pharmaceuticals Ltd.
• Nipro Corporation
• Thermo Fisher Scientific Inc.
• Samsung Biologics
• Laboratory Corporation of America Holdings
• Siegfried Holding Ag
• Catalent, Inc
• Lonza Group AG
• Recipharm Ab
• Piramal Pharma Solutions
• Cordenpharma International
• Cambrex Corporation
• Wuxi Apptec

Segments Covered in the Report

By Service Type

• Active Pharmaceutical Ingredient (API) Manufacturing
  
  • Small Molecule
  • Large Molecule
  • High Potency (HPAPI)
• Finished Dosage Formulation (FDF) Development and Manufacturing
  
  • Solid Dose Formulation
  • Tablets
  • Others (Capsules, Powders, etc.)
  • Liquid Dose Formulation
  • Injectable Dose Formulation
• Secondary Packaging

By Research Phase

• Pre-clinical
• Phase I
• Phase II
• Phase III
• Phase IV